Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OTLK vs CABA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OTLK Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

OTLK Overall Winner 6-Pillar Tally: OTLK 3 – 2 CABA (1 Tie) Matrix Metrics: OTLK 7 – 2 CABA

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Cabaletta Bio, Inc. (CABA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CABA carries 47.0/100 (HOLD) at $1.12 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CABA 47.0/100 HOLD) and 1.47β · 79% Vol risk profile, whereas CABA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CABA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OTLK vs CABA
OTLK NASDAQ Head-to-Head Winner
Outlook Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.40
-4.04% 1D
Market Cap $107.1M
TTM Revenue N/A
Forward P/E 2.9x
Beta / 30D Vol 1.47β · 79% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 71.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.48 · SMA50: $0.56
CABA NASDAQ
Cabaletta Bio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.12
-12.11% 1D
Market Cap $286.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.85β · 101% Vol
Unified Composite Score
47.0 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 66.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -26.3%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $1.43 · SMA50: $1.88

6-Pillar Scorecard Institutional Category Breakdown (OTLK 3 – 2 CABA)

Columns: Metric · OTLK · CABA
1. Valuation Multiples OTLK
Forward P/E 2.9x N/M
Trailing P/E 2.9x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CABA
Revenue Growth (YoY) -99.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $107.1M $286.9M
3. Profitability & Quality OTLK
Gross Margin N/A N/A
Operating Margin 4781.8% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -3.6% -89.5%
4. Balance Sheet & Cash Flow CABA
Cash Generation (TTM) -$56M -$163M
Cash Flow Margin N/A N/A
Net Cash / Leverage $7.2M Net Debt $276M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OTLK
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 181.3% (55th %ile) 129.7% (30th %ile)
Put/Call OI Skew 0.26x (Call-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OTLK (7) vs CABA (2)
Institutional Metric OTLK CABA Criterion Row Edge
Market Capitalization
Scale
$107.1M $286.9M Larger Scale CABA
Trailing P/E Ratio
Valuation
2.9x N/M Lower Multiple OTLK
Forward P/E Ratio
Valuation
2.9x N/M Lower Multiple OTLK
Revenue Growth (YoY)
Growth
-99.4% +0.0% Higher Growth CABA
Operating Margin (TTM)
Profitability
4781.8% 0.0% Higher Margin OTLK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-3.6% -89.5% Higher ROE OTLK
52-Week Range Position
Momentum
10% ($0–$3) 0% ($1–$4) Stronger Trend OTLK
Beta / 30D Volatility
Risk Regime
1.47β · 79% Vol 1.85β · 101% Vol Lower Realized Risk OTLK
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 47.0 / 100 (HOLD) Higher Composite OTLK
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$56M ($7.2M Net Debt) -$163M ($276M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OTLK +1.39 pp
OTLK: -18.82% · CABA: -20.21%
3M Horizon OTLK +17.95 pp
OTLK: -43.39% · CABA: -61.34%
6M Horizon OTLK +138.72 pp
OTLK: +72.91% · CABA: -65.81%
1Y Horizon CABA +21.12 pp
OTLK: -73.04% · CABA: -51.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OTLK vs CABA. Trailing 12-month operating profitability (OTLK 4781.8% vs CABA 0.0%) and valuation multiples (OTLK 2.9x vs CABA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OTLK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin4781.8%
ROE / Fwd P/E-3.6% · 2.9x
CABA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-89.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OTLK BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 181.3%
IV Percentile 55th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OTLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CABA BREAKDOWN
135d in phase · OBV NEUTRAL
Current IV 129.7%
IV Percentile 30th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CABA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OTLK Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CABA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $286.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OTLK vs CABA Key Questions & Quantitative Answers

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Cabaletta Bio, Inc. (CABA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CABA carries 47.0/100 (HOLD) at $1.12 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CABA 47.0/100 HOLD) and 1.47β · 79% Vol risk profile, whereas CABA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CABA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CABA leads the Growth & Scale pillar: OTLK posts -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin), compared with CABA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, OTLK generates N/A in USD-normalized revenue versus N/A for CABA. In operating R&D and SG&A reinvestment, OTLK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CABA.

OTLK screens cheaper on headline valuation multiples. OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CABA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OTLK (-3.6% ROE) versus CABA (-89.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk). By comparison, CABA carries 129.7% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.